In a report published on Monday, Jefferies analyst Oren G. Livnat downgraded Elan Corp ELN from Buy to Hold and lowered the price target on the company from $19 to $15.
In the report, Jefferies stated, "LN agreed to be acquired by Perrigo for ~$8.6B or $16.50/shr (based on prior PRGO stock price), a >40% premium to where ELN was following Bapi Ph.3 failure, and >25% above the last Royalty Pharma hostile bid. Given the open/ formal sales process, we do not see higher bids now and expect ELN shareholder approval and close by end'13."
Elan Corp closed on Friday at $14.93.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in